Page last updated: 2024-11-02

picotamide and Myeloproliferative Disorders

picotamide has been researched along with Myeloproliferative Disorders in 2 studies

picotamide: has anticoagulant & fibrinolytic properties; structure

Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Research Excerpts

ExcerptRelevanceReference
"Bleeding and thrombosis are major causes of morbidity and mortality in patients with chronic myeloproliferative disorders."1.29Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders. ( Carpi, A; Ferretti, A; Nicolini, A; Sagripanti, A, 1996)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sagripanti, A1
Ferretti, A1
Nicolini, A1
Carpi, A1
Rafanelli, D1
Grossi, A1
Vannucchi, AM1
Cinotti, S1
Morfini, M1
Ferrini, PR1

Other Studies

2 other studies available for picotamide and Myeloproliferative Disorders

ArticleYear
Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1996, Volume: 50, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Follow-Up Studies; Hemorrhage;

1996
The effect of picotamide on platelet function in patients with myeloproliferative disorders.
    Thrombosis and haemostasis, 1990, Jun-28, Volume: 63, Issue:3

    Topics: Humans; Myeloproliferative Disorders; Phthalic Acids; Pilot Projects; Platelet Aggregation Inhibitor

1990